2c68 › Citations

Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.

Richardson CM, Williamson DS, Parratt MJ, Borgognoni J, Cansfield AD, Dokurno P, Francis GL, Howes R, Moore JD, Murray JB, Robertson A, Surgenor AE, Torrance CJ
Bioorg Med Chem Lett 16 1353-7 (2006)
Related entries: 2c69, 2c6i, 2c6k, 2c6l, 2c6m, 2c6o, 2c6t

Cited: 18 times
EuropePMC logo PMID: 16325401

Abstract

Crystallographic and modelling data, in conjunction with a medicinal chemistry template-hopping approach, led to the identification of a series of novel and potent inhibitors of human cyclin-dependent kinase 2 (CDK2), with selectivity over glycogen synthase kinase-3beta (GSK-3beta). One example had a CDK2 IC(50) of 120 nM and showed selectivity over GSK-3beta of 167-fold.

Articles - 2c68 mentioned but not cited (2)

  1. Identification, Characteristics and Mechanism of 1-Deoxy-N-acetylglucosamine from Deep-Sea Virgibacillus dokdonensis MCCC 1A00493. Huang D, Shao ZZ, Yu Y, Cai MM, Zheng LY, Li GY, Yu ZN, Yi XF, Zhang JB, Hao FH. Mar Drugs 16 E52 (2018)
  2. Rapid Identification of Inhibitors and Prediction of Ligand Selectivity for Multiple Proteins: Application to Protein Kinases. Ma Z, Huang SY, Cheng F, Zou X. J Phys Chem B 125 2288-2298 (2021)


Reviews citing this publication (2)

  1. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Mazanetz MP, Fischer PM. Nat Rev Drug Discov 6 464-479 (2007)
  2. 1,2,4-Triazolo[1,5-a]pyrimidines in drug design. Oukoloff K, Lucero B, Francisco KR, Brunden KR, Ballatore C. Eur J Med Chem 165 332-346 (2019)

Articles citing this publication (14)

  1. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Huang D, Zhou T, Lafleur K, Nevado C, Caflisch A. Bioinformatics 26 198-204 (2010)
  2. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Tripathi SK, Muttineni R, Singh SK. J Theor Biol 334 87-100 (2013)
  3. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X. Eur J Med Chem 92 754-765 (2015)
  4. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. Jorda R, Havlícek L, McNae IW, Walkinshaw MD, Voller J, Sturc A, Navrátilová J, Kuzma M, Mistrík M, Bártek J, Strnad M, Krystof V. J Med Chem 54 2980-2993 (2011)
  5. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. Richardson CM, Nunns CL, Williamson DS, Parratt MJ, Dokurno P, Howes R, Borgognoni J, Drysdale MJ, Finch H, Hubbard RE, Jackson PS, Kierstan P, Lentzen G, Moore JD, Murray JB, Simmonite H, Surgenor AE, Torrance CJ. Bioorg Med Chem Lett 17 3880-3885 (2007)
  6. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. Wang L, Tian Y, Chen W, Liu H, Zhan P, Li D, Liu H, De Clercq E, Pannecouque C, Liu X. Eur J Med Chem 85 293-303 (2014)
  7. 6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity. Boschi D, Tosco P, Chandra N, Chaurasia S, Fruttero R, Griffin R, Wang LZ, Gasco A. Eur J Med Chem 68 333-338 (2013)
  8. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling. Yuan H, Liu H, Tai W, Wang F, Zhang Y, Yao S, Ran T, Lu S, Ke Z, Xiong X, Xu J, Chen Y, Lu T. SAR QSAR Environ Res 24 795-817 (2013)
  9. Biological Activity of Triazolopyrimidine Copper(II) Complexes Modulated by an Auxiliary N-N-Chelating Heterocycle Ligands. Ruta LL, Farcasanu IC, Bacalum M, Răileanu M, Rostas AM, Daniliuc C, Chifiriuc MC, Măruțescu L, Popa M, Badea M, Iorgulescu EE, Olar R. Molecules 26 6772 (2021)
  10. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, Wang LZ, Hardcastle IR. Org Biomol Chem 5 1577-1585 (2007)
  11. Computational design of targeted inhibitors of polo-like kinase 1 (plk1). Jani KS, Dalafave DS. Bioinform Biol Insights 6 23-31 (2012)
  12. Design, Synthesis and Biological Evaluation of [1,2,4]Triazolo[1,5-a]pyrimidine Indole Derivatives against Gastric Cancer Cells MGC-803 via the Suppression of ERK Signaling Pathway. Yu GX, Hu Y, Zhang WX, Tian XY, Zhang SY, Zhang Y, Yuan S, Song J. Molecules 27 4996 (2022)
  13. Design, synthesis, and biological investigation of selective human carbonic anhydrase II, IX, and XII inhibitors using 7-aryl/heteroaryl triazolopyrimidines bearing a sulfanilamide scaffold. Romagnoli R, De Ventura T, Manfredini S, Baldini E, Supuran CT, Nocentini A, Brancale A, Bortolozzi R, Manfreda L, Viola G. J Enzyme Inhib Med Chem 38 2270180 (2023)
  14. Study on Wangzaozin-A-Inducing Cancer Apoptosis and Its Theoretical Protein Targets. Chen J, Wang S, Lu X. Technol Cancer Res Treat 15 589-596 (2016)


Quick links